Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three EU Countries Strike Landmark Joint Zolgensma Pricing Deal

Executive Summary

BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.

You may also be interested in...



Joint Procurement Rising Up EU Agenda As Future Access Mechanism

Joint procurement is of growing interest in the EU as a means of providing access to expensive innovative medicines.

Gene Therapy Libmeldy Undergoes Cross-Country HTA In Europe

Cross-country drug access coalition BeNeLuxA is reviewing the costly one-off gene therapy for children with metachromatic leukodystrophy.

European Countries Should Join Forces To Lower Prices of Zolgensma & Kaftrio

The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel